Chronomics
London, United Kingdom· Est.
Chronomics offers an AI‑powered multi‑omics diagnostic platform that turns complex biomarker data into actionable health insights.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $10M
AI Company Overview
Chronomics offers an AI‑powered multi‑omics diagnostic platform that turns complex biomarker data into actionable health insights.
AgingMetabolic HealthCardiovascular DiseaseOncology
Technology Platform
An AI‑driven, end‑to‑end multi‑omics platform that integrates UKAS‑accredited laboratory testing with cloud‑based analytics to generate clinically validated biomarker panels.
Opportunities
Expansion into US and EU markets, regulatory clearance for cancer‑early‑detection panels, and subscription‑based digital health monitoring services.
Risk Factors
Regulatory hurdles for multi‑omics diagnostics, data‑privacy compliance, and competition from larger genomics and AI‑driven diagnostic firms.
Competitive Landscape
Chronomics competes with 23andMe, Myriad Genetics, Grail and Tempus, differentiating itself through an integrated, AI‑powered multi‑omics platform and end‑to‑end diagnostic logistics.